← Back to Search

HyperSight Imaging for Cancer

N/A
Recruiting
Research Sponsored by Varian, a Siemens Healthineers Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patient has biopsy confirmed malignancy and recommendation for definitive or palliative radiation to the head and neck, breast, lungs, upper GI structures, or pelvis.
Patient has ECOG performance status 0-2.
Must not have
Patient receives palliative radiation for 5 or fewer fractions.
Patient has known genetic pre-disposition for sensitivity to radiation (e.g., Li Fraumeni).
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights
No Placebo-Only Group

Summary

This trial aims to test a new imaging technology called "HyperSight" that may improve the accuracy and quality of radiation therapy. Currently, there are limitations with the current imaging technology, including long acquisition

Who is the study for?
This trial is for individuals with various cancers (pelvic, head and neck, breast, lung, gastric, gastrointestinal tumors) who require precise radiation therapy. Participants should need image-guided radiation treatment but are not specified by other inclusion or exclusion criteria in the provided information.
What is being tested?
The study is testing 'HyperSight Imaging,' a new type of imaging technology designed to improve the accuracy of radiation therapy. It aims to overcome limitations like long scan times and poor image quality seen with conventional cone beam computed tomography (CBCT).
What are the potential side effects?
Since this trial focuses on an imaging technique rather than a drug or biological therapy, traditional side effects are not applicable. However, there may be risks associated with exposure to additional radiation from improved imaging if used frequently.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have a confirmed cancer diagnosis and need radiation therapy in specific areas.
Select...
I am able to get out of my bed or chair and move around.
Select...
I am 18 years old or older.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am getting a short course of radiation therapy for symptom relief.
Select...
I have a genetic condition that makes me sensitive to radiation.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Fraction of patients whose HyperSight CBCT images meet the criteria for CBCT-based treatment planning.
Secondary study objectives
Breath hold tolerance
Comparison of anatomical structure contours defined on HyperSight and conventional imaging.
Fraction of patients whose HyperSight CBCT images meet the criteria for CBCT-based treatment planning by anatomical site
+6 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: HyperSight Imaging armExperimental Treatment1 Intervention
Subjects are imaged with the new HyperSight CBCT imaging system.

Find a Location

Who is running the clinical trial?

Varian, a Siemens Healthineers CompanyLead Sponsor
34 Previous Clinical Trials
7,187 Total Patients Enrolled
~24 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top